1. Swerdlow S.H.C.E., Harris N.L., Jaffe E.S., Pileri S.A., Stein H., Thiele J., Arber D.A., Hasserjian R.P., Le Beau M.M., Orazi A., Siebert R. WHO classification of tumours of hematopoietic and lymphoid tissues. Revised 4th edition ed. Lyon: IARC; 2017.
2. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020
3. Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma;Gribben;J. Clin. Oncol.,2015
4. Lenalidomide after stem-cell transplantation for multiple myeloma;McCarthy;N. Engl. J. Med.,2012
5. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma;Attal;N. Engl. J. Med.,2012